ライフサイエンスコーパス: P-glycoprotein

1 dues for interaction of small molecules with P-glycoprotein.

2 d by multiple ABC transporters, particularly P-glycoprotein.

3 may be influenced by the multi-drug exporter P-glycoprotein.

4 rom the fetus toward the mother by placental P-glycoprotein.

5 and circumvented drug resistance mediated by P-glycoprotein.

6 and Messa/Dx5 cell lines, which overexpress P-glycoprotein.

7 of multidrug resistant cells overexpressing P-glycoprotein.

8 rapies with limited brain penetration due to P-glycoprotein.

9 s because of increased nuclear expression of P-glycoprotein.

10 likelihood of brain uptake being affected by P-glycoprotein.

11 t olaparib-resistant tumors that overexpress P-glycoprotein.

12 ier-related ATP-binding cassette transporter P-glycoprotein.

13 kely an efficiently transported substrate of P-glycoprotein.

14 e, which encodes the drug efflux transporter P-glycoprotein.

15 osis transmembrane conductance regulator and P-glycoprotein.

16 sm, and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive perme

17 have cleavage activities on its target gene P-glycoprotein 11, a broad substrate efflux pump across

18 As a substrate of P-glycoprotein, a drug efflux pump associated with multi

19 as shown in vitro to be a substrate of human P-glycoprotein, a drug-transporter involved in all steps

20 e ATP-binding cassette family like the human P-glycoprotein (ABCB1 or Pgp) are responsible for many f

21 barrier (BBB) because of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance prot

22 firmed expression and functional activity of P-glycoprotein (ABCB1) and breast cancer resistance prot

23 P-glycoprotein (ABCB1) is expressed at the blood-retina

24 lux transporters at the blood-brain barrier, P-glycoprotein (ABCB1), multidrug resistance associated

25 tte (ABC) transmembrane efflux pumps such as P-glycoprotein (ABCB1), multidrug resistance protein 1 (

26 oprotein and its human counterpart, the MDR1 P-glycoprotein, ABCB1.

27 ls of TAP built on the crystal structures of P-glycoprotein, ABCB10, and Sav1866.

28 t that reduced rCBF has on assessment of BBB P-glycoprotein activity and suggests that impaired P-gly

29 20P, can rapidly and reversibly reduce basal P-glycoprotein activity and thus improve delivery of sma

30 ase activity mimicked the effects of VEGF on P-glycoprotein activity and Tyr-14 phosphorylation of ca

31 BBB P-glycoprotein activity in brain regions affected by AD

32 We compared P-glycoprotein activity in mild-AD patients (n = 9) and

33 tivity and protein expression; SFN increased P-glycoprotein activity in mouse spinal cord capillaries

34 We assessed P-glycoprotein activity in vivo in patients with tempora

35 2 are required for C1P-mediated increases in P-glycoprotein activity independent of transporter prote

36 We tested the hypothesis that BBB P-glycoprotein activity is diminished in Alzheimer disea

37 oprotein activity and suggests that impaired P-glycoprotein activity may contribute to cerebral beta-

38 Higher P-glycoprotein activity was associated with higher seizu

39 BBB P-glycoprotein activity was expressed as the (11)C-verap

40 Compared with controls, BBB P-glycoprotein activity was significantly lower in the p

41 oliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified.

42 for tissue hypoxia, and (11)C-verapamil for P-glycoprotein activity, in comparison with (15)O-water

43 aseline K1, corresponding to higher baseline P-glycoprotein activity, than seizure-free patients in i

44 ion or translation abolished upregulation of P-glycoprotein activity.

45 ncreases after tariquidar correspond to high P-glycoprotein activity.

46 of specific genes and significantly elevated p-glycoprotein activity.

47 ) blocked the effects of SFN and nutlin-3 on P-glycoprotein activity.

48 on, and the p53-activator nutlin-3 increased P-glycoprotein activity.

49 of multiple sclerosis, also rapidly reduced P-glycoprotein activity; similar effects were found with

50 tracers to assess the transport activity of P-glycoprotein (adenosine triphosphate-binding cassette

51 Structural comparison of MRP1 and P-glycoprotein advances our understanding of the common

52 However, the silencing of P-glycoprotein, although capable of impeding drug transp

53 Herein, we report findings that P-glycoprotein, an ATP-dependent efflux drug transporter

54 transport activity and protein expression of P-glycoprotein, an ATP-driven drug efflux pump and a cri

55 P-glycoprotein, an ATP-driven drug efflux pump, is a maj

56 P-glycoprotein, an ATP-driven efflux pump, regulates per

57 multidrug efflux protein MDR1 (also known as P-glycoprotein and ABCB1).

58 MSCs overexpress efflux transporters such as P-glycoprotein and are highly drug resistant.

59 (ii) this overexpression appears specific to P-glycoprotein and does not affect other transporters; (

60 P-glycoprotein and drug efflux activity transfers were f

61 be excellent substrates of the murine ABCB1A P-glycoprotein and its human counterpart, the MDR1 P-gly

62 -hydroxyeicosatetraenoic acid that regulated P-glycoprotein and junction proteins, respectively, ther

63 onfirmed their potential to inhibit the fish P-glycoprotein and modulate toxicity of other xenobiotic

64 ve, namely, 1p, was selective for ABCG2 over P-glycoprotein and MRP1, appeared not to be transported

65 class of galloyl-based modulators targeting P-glycoprotein and MRP1.

66 esistance study in cell lines overexpressing P-glycoprotein and showed that some of these inhibitors

67 anisms of drug resistance, the expression of P-glycoprotein and the betaIII isotype of tubulin.

68 rug resistance mediated by the expression of P-glycoprotein and the betaIII isotype of tubulin.

69 onolayer and that PHIP-M1 is a substrate for P-glycoprotein and the multiple drug resistance 2 transp

70 porters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (also known as MRP1) whose inh

71 penetration, acceptable ADME properties, no P-glycoprotein, and no hERG liability.

72 ining l-asparaginase and drugs unaffected by P-glycoprotein are most effective.

73 Mammalian P-glycoproteins are active drug efflux transporters loca

74 and selective downregulation of endothelial p-glycoprotein at the blood-brain barrier that occurs in

75 rug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidr

76 Measurement of the P-glycoprotein-ATPase activity as a function of concentr

77 t unexpectedly strong down-modulation of the P-glycoprotein-ATPase by certain detergents.

78 P-glycoprotein-ATPase inhibition due to membrane disorde

79 P-glycoprotein-ATPase is an efflux transporter of broad

80 2, p53, and NF-kappaB in the upregulation of P-glycoprotein, Bcrp, and Mrp2 at blood-CNS barriers.

81 or mouse brain capillaries to SFN increased P-glycoprotein, Bcrp, and Mrp2 transport activity and pr

82 es demonstrated that effective inhibition of P-glycoprotein by DDB analogues dramatically elevated th

83 Interestingly, a knockdown of P-glycoprotein by RNAi was found to impede Sertoli cell

84 ATP-binding cassette transporter other than P-glycoprotein can affect in vivo tissue sensitivity tow

85 If this relation is confirmed, and P-glycoprotein can be identified as a contributor to pha

86 y the ATP-binding cassette (ABC) transporter P-glycoprotein contributes to clinical resistance to ant

87 Inhibition of P-glycoprotein could partly resensitize sarcomatoid tumo

88 n inhibitors of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (cyclosporine, ketoconazole, ritonavir, c

89 ral drug-resistant cell lines with activated P-glycoprotein drug efflux pumps compared to drug-sensit

90 tine and paclitaxel through up-regulation of P-glycoprotein drug efflux pumps.

91 The P-glycoprotein drug pump protects us from toxins.

92 sed with drug concentration and exceeded the p-glycoprotein efflux when the latter was saturated.

93 properties such as permeation and especially P-glycoprotein efflux.

94 long-acting, and noncompetitive modulator of P-glycoprotein export function that may offer therapeuti

95 t to doxorubicin despite significantly lower P-glycoprotein expression in the DoxR-v cells.

96 enhanced DNA damage and obvious reduction of P-glycoprotein expression in the resistant cells treated

97 P-glycoprotein expression is known to be controlled by g

98 tance, and that the specific upregulation of P-glycoprotein expression is likely to be associated wit

99 ood-brain barrier permeability and increased P-glycoprotein expression.

100 )C-laniquidar is a newly developed tracer of P-glycoprotein expression.

101 axel response, despite an increase in Abcb1 (P-glycoprotein) expression that was sufficient to explai

102 ineties, we generated knockouts of the three P-glycoprotein genes of mice, the Mdr1a, Mdr1b, and Mdr2

103 Another SNP in CYP2B6 (983TT) and a p-glycoprotein haplotype affected AUCs without substanti

104 protein (humans, ABCG2; rodents, Abcg2) and P-glycoprotein (humans, ABCB1; rodents, Abcb1a/b) affect

105 mortem human brain tissue support a role for P-glycoprotein in clearance of cerebral beta-amyloid acr

106 ar, our findings show that the expression of P-glycoprotein in humans is compatible with the inherent

107 ction was not dependent on the expression of P-glycoprotein in MDR cells.

108 here is a highly localized overexpression of P-glycoprotein in the epileptogenic hippocampus of patie

109 nded-release venlafaxine (all substrates for P-glycoprotein) in a large randomized, prospective, prag

110 ionary related in full transporters, such as P-glycoprotein, in which substrates bind preferentially,

111 cells with verapamil, a general inhibitor of P-glycoprotein, increased nuclear translocation of doxor

112 area, and concomitant use of cytochrome 3A4/P-glycoprotein inducers.

113 ostaglandin E2 receptors 1 and 2), abolished P-glycoprotein induction by C1P.

114 P-glycoprotein induction or activation to increase cereb

115 role for drug-drug interactions that lead to P-glycoprotein inhibition in buprenorphine-associated fa

116 associated with days of coadministration of P-glycoprotein inhibitor (r=0.35; p=0.0004).

117 Use of a P-glycoprotein inhibitor did not further increase the ef

118 G-829 as a novel, noncompetitive, and potent P-glycoprotein inhibitor that overcomes in vitro and in

119 olerability of NSC23925b, a novel and potent P-glycoprotein inhibitor, in rodents.

120 PSC833, a powerful P-glycoprotein inhibitor, significantly enhanced bupreno

121 Pretreatment with a P-glycoprotein inhibitor, which blocks blood-brain barri

122 trols then received a 30-min infusion of the P-glycoprotein-inhibitor tariquidar followed by another

123 presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors in the Rivaroxaban Once Daily

124 ere receiving concomitant treatment with the P-glycoprotein inhibitors quinidine or verapamil) or war

125 CL) cells with romidepsin in the presence of P-glycoprotein inhibitors to prevent transporter upregul

126 ime 0 to infinity for colchicine plus CYP3A4/P-glycoprotein inhibitors versus colchicine alone were >

127 bodyweight [</=60 kg], or concomitant use of P-glycoprotein inhibitors) were present.

128 of colchicine, but not the reference CYP3A4/P-glycoprotein inhibitors, were determined, and the phar

129 he approved on-label regimen of known CYP3A4/P-glycoprotein inhibitors.

130 ontinued during therapy with multiple CYP3A4/P-glycoprotein inhibitors.

131 dministered with most of the selected CYP3A4/P-glycoprotein inhibitors.

132 with >/= 1 combined cytochrome P450 3A4 and P-glycoprotein inhibitors.

133 hown a clear trend between lipophilicity and P-glycoprotein inhibitory activity for a class of galloy

134 onedarone increases digoxin concentration by P-glycoprotein interaction.

135 less, or concomitant medication with potent P-glycoprotein interaction.

136 psychotropic agents via cytochrome P450 and p-glycoprotein interactions.

137 It is a close homologue of human P-glycoprotein involved in multidrug resistance, and it

138 Our objectives were to assess P-glycoprotein involvement in norbuprenorphine transport

139 f doxorubicin due to increased expression of P-glycoprotein is associated with doxorubicin resistance

140 nd does not affect other transporters; (iii) P-glycoprotein is expressed on the vascular endothelium

141 These findings indicate that P-glycoprotein is involved in BTB restructuring during s

142 Wild-type and P-glycoprotein knockout female Friend virus B-type mice.

143 significantly reduced in PSC833-treated and P-glycoprotein-knockout mice (p < .001), supporting P-gl

144 In P-glycoprotein-knockout mice, buprenorphine-related effe

145 However, lack of brain penetration and P-glycoprotein liability makes this scaffold unsuitable

146 expression of the multidrug efflux transport P-glycoprotein may play an important role in pharmacores

147 res intestinal absorption by the efflux pump P-glycoprotein MDR1 (multidrug resistant-1), encoded by

148 cells overexpressing the efflux transporter P-glycoprotein (MDR1, P-gp, ABCB1).

149 ced endosomal escape; (vi) the inhibition of P-glycoprotein mediated drug efflux; and (vii) the TAT-m

150 oducing fluorine on the risk of encountering P-glycoprotein mediated efflux (as measured by MDR efflu

151 nephine A (1) is a noncytotoxic inhibitor of P-glycoprotein-mediated drug efflux in multidrug-resista

152 Third, to avoid P-glycoprotein-mediated drug efflux, we further designed

153 protein-knockout mice (p < .001), supporting P-glycoprotein-mediated norbuprenorphine transport at th

154 estructuring during spermatogenesis but that P-glycoprotein-mediated restructuring does not "open up"

155 L) absorption and metabolism are affected by p-glycoprotein-mediated transport and CYP3A enzyme activ

156 sporters at the blood-brain barrier, such as P-glycoprotein, might contribute to pharmacoresistance b

157 ne receptor (CAR) as a positive regulator of P-glycoprotein, multidrug resistance-associated protein

158 in genes of mice, the Mdr1a, Mdr1b, and Mdr2 P-glycoproteins, now known as Abcb1a, Abcb1b, and Abcb4,

159 genes: CYP3A4, CYP3A5, ABCB1 (MDR1; encoding P-glycoprotein), NR1I2 (encoding the pregnane X receptor

160 lls in vivo by suppressing expression of the P-glycoprotein Oca2.

161 ofound effect of the drug-transporting ABCB1 P-glycoprotein on the pharmacokinetics of drugs in human

162 entrations of HG-829 restored sensitivity to P-glycoprotein oncolytic substrates.

163 binding cassette (ABC) transporter proteins, P-glycoprotein or breast cancer resistance protein.

164 ontributor to pharmacoresistance, overcoming P-glycoprotein overactivity could be investigated as a p

165 othesis that there is an association between P-glycoprotein overactivity in some regions of the brain

166 pectrometry to identify metabolic changes in P-glycoprotein overexpressing T-cell acute lymphoblastic

167 and 44 strongly inhibited the growth of the P-glycoprotein-overexpressing multi-drug-resistant cell

168 ARAP 22 showed strong inhibition of the P-glycoprotein-overexpressing NCI-ADR-RES and Messa/Dx5M

169 r initial acute injury for the prevention of P-glycoprotein overexpression, and thus this one potenti

170 he occurrence of seizures appears central to P-glycoprotein overexpression.

171 of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance prote

172 eased activity of efflux transporters, e.g., P-glycoprotein (P-gp) and breast cancer resistance prote

173 tive ligand of VDR, resulted in higher brain P-glycoprotein (P-gp) and lower soluble Abeta levels, ef

174 cess limited by drug efflux proteins such as P-glycoprotein (P-gp) at the membrane of brain capillary

175 The P-glycoprotein (P-gp) drug pump (ABCB1) has two transmem

176 S screening hit (1) that exhibited both high p-glycoprotein (P-gp) efflux ratios in rat and human and

177 As a substrate of the P-glycoprotein (P-gp) efflux transporter, quinacrine is

178 ssion and activity of the efflux transporter P-glycoprotein (P-gp) encoded by ABCB1 in human hepatoma

179 The drug efflux function of P-glycoprotein (P-gp) encoded by MDR1 can be influenced

180 ensitizers for photodynamic therapy (PDT) in P-glycoprotein (P-gp) expressing cells.

181 ecrease in ABCB1/multidrug resistance (MDR)1 p-glycoprotein (p-gp) expression.

182 Q-starch/siRNA complexes efficiently induced P-glycoprotein (P-gp) gene silencing in the human ovaria

183 The drug efflux pump P-glycoprotein (P-gp) has been shown to promote multidru

184 The mechanism reducing blood-brain barrier P-glycoprotein (P-gp) in Alzheimer's disease is poorly u

185 and testes are limited due to high levels of P-glycoprotein (P-gp) in the luminal membranes of brain

186 lood-brain barrier is the efflux transporter P-glycoprotein (P-gp) in the luminal plasma membrane of

187 DR) is to deliver anticancer drug along with P-glycoprotein (P-gp) inhibitor simultaneously.

188 P-glycoprotein (P-gp) is a multidrug transporter that us

189 P-glycoprotein (P-gp) is a polyspecific ATP-dependent tr

190 P-glycoprotein (P-gp) is a well-known membrane transport

191 P-glycoprotein (P-gp) is an ATP binding cassette transpo

192 P-glycoprotein (P-gp) is an ATP-binding cassette drug pu

193 P-glycoprotein (P-gp) is an ATP-binding cassette transpo

194 The drug efflux transporter P-glycoprotein (P-gp) is highly expressed on brain endot

195 ATP-binding cassette (ABC) drug transporter P-glycoprotein (P-gp) is often responsible for the failu

196 P-glycoprotein (P-gp) is one of the best-known mediators

197 The development of P-glycoprotein (P-gp) ligands remains of considerable in

198 ing hydrogen bond donors (HBDs) and reducing P-glycoprotein (P-gp) mediated efflux.

199 P-glycoprotein (P-gp) plays a crucial role in the develo

200 We found that P-glycoprotein (P-gp) sequestered CA within the Golgi co

201 P-glycoprotein (P-gp) serves as a therapeutic target for

202 study, we demonstrate that the inhibition of P-glycoprotein (P-gp) significantly increases brain pene

203 cking the multidrug resistance protein Mdr1a P-glycoprotein (P-gp) was generated using a rat Mdr1a-sp

204 Zosuquidar, which modulates P-glycoprotein (P-gp) with minimal delay of anthracyclin

205 grows in tumours and functionally decreases P-glycoprotein (P-gp), a multidrug resistance transporte

206 P-glycoprotein (P-gp), a promiscuous drug efflux pump, h

207 increased the mRNA and protein expression of p-glycoprotein (P-gp), a subfamily of ATP-binding casset

208 ramide (dLop) images the in vivo function of P-glycoprotein (P-gp), a transporter that blocks the ent

209 rimary determinant of CNS drug permeation is P-glycoprotein (P-gp), an endogenous blood-brain barrier

210 ractivity of multidrug transporters, such as P-glycoprotein (P-gp), at the blood-brain barrier.

211 pumps, the ATP-Binding Cassette transporter P-glycoprotein (P-gp), consists of two homologous halves

212 Using P-glycoprotein (P-gp), Cyp3a-, and P-gp/Cyp3a knockout m

213 regulation of a multidrug resistant protein, P-glycoprotein (P-gp), suggesting an active drug efflux

214 e is connected to overexpression of membrane P-glycoprotein (P-gp), which acts as an energy dependent

215 mulate the ATPase activity of purified human P-glycoprotein (P-gp)-His(10), and their ability to prom

216 epsy and subsequently to study if changes in P-glycoprotein (P-gp)-mediated efflux of flumazenil at t

217 es at the blood-brain barrier (BBB), such as P-glycoprotein (P-gp)-mediated efflux, can limit brain u

218 ns such as the multidrug resistance protein, P-glycoprotein (P-gp).

219 ds 1-5 in biochemical assays with ABCC10 and P-glycoprotein (P-gp).

220 rate of the multidrug resistance transporter P-glycoprotein (P-gp).

221 of the increased nuclear expression of MDR1/P-glycoprotein (P-gp).

222 multidrug resistant cell line overexpressing P-glycoprotein (P-gp).

223 otosensitizer is also a potent stimulator of P-glycoprotein (P-gp).

224 transiently express c-Kit and stably express P-glycoprotein (P-gp)/multi-drug resistance type 1 (MDR1

225 f cell lines expressing the drug efflux pump P-glycoprotein (P-gp, ABCB1) and MRP1 (ABCC1).

226 activities against BCRP and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance pr

227 clinically important because drug pumps like P-glycoprotein (P-gp, ABCB1) confer multidrug resistance

228 The P-glycoprotein (P-gp, ABCB1) drug pump protects us from

229 P-glycoprotein (P-gp, ABCB1) is a member of the ATP-bind

230 P-glycoprotein (P-gp, ABCB1) is an ATP-binding cassette

231 The multidrug transporter P-glycoprotein (P-gp, ABCB1) is an ATP-dependent pump th

232 P-glycoprotein (P-gp, ABCB1) is an important part of the

233 in the heart and increased the expression of P-glycoprotein (P-gp, ABCB1), an ATP binding cassette th

234 P-Glycoprotein (P-gp, ABCB1), multidrug resistance-assoc

235 er with mutant p53 and induces MDR1 gene and P-glycoprotein (P-gp, ABCB1), resulting in a multidrug-r

236 LP), and presence of the efflux transporter, P-glycoprotein (P-gp, ABCB1).

237 vestigated compounds had low affinity toward P-glycoprotein (P-gp, ABCB1).

238 P-glycoprotein (P-gp, MDR1) is a promiscuous drug efflux

239 The ABC transporters P-glycoprotein (P-gp, official gene symbol ABCB1) and br

240 (11)C-metoclopramide transport by P-glycoprotein (P-gp; ABCB1) and the breast cancer resis

241 P-glycoprotein (P-gp; ABCB1) is an ABC drug pump that pr

242 uman ATP-binding cassette (ABC) transporter, P-glycoprotein (P-gp; ABCB1), mediates the ATP-dependent

243 wn substrate for efflux transporters such as P-glycoprotein (P-gp; MDR1, ABCB1), significantly less i

244 12, or 24 mg/kg/h) of cyclosporine A (CsA, a P-glycoprotein [P-gp] inhibitor).

245 demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate.

246 rodrug and MDR gene-silencing siRNAs (Bcl-2, P-glycoprotein [P-gp], and survivin) via encapsulation a

247 e triphosphate-binding cassette transporters P-glycoprotein (Pgp) and breast cancer resistance protei

248 c resistance to olaparib caused by increased P-glycoprotein (Pgp) drug efflux transporter expression.

249 of vinca derivatives 16-18 able to modulate P-glycoprotein (Pgp) efflux activity is reported.

250 Overexpression of P-glycoprotein (Pgp) increases multidrug resistance (MDR

251 P-glycoprotein (Pgp) is an ATP-binding cassette (ABC) tr

252 P-glycoprotein (Pgp) is an efflux pump important in mult

253 P-glycoprotein (Pgp) is one of the most biomedically rel

254 The overexpression of P-glycoprotein (Pgp) is thought to be an important mecha

255 Multidrug resistance (MDR) mediated by P-glycoprotein (Pgp) represents a significant impediment

256 uestration of the novel anti-tumor agent and P-glycoprotein (Pgp) substrate, di-2-pyridylketone-4,4-d

257 Saridegib, a known P-glycoprotein (Pgp) substrate, induced Pgp activity in

258 Localization of the drug transporter P-glycoprotein (Pgp) to the plasma membrane is thought t

259 resistance, are not only able to bypass the P-glycoprotein (Pgp) transporter, due to their nano-size

260 of administration and the inhibition of the P-glycoprotein (Pgp) transporter.

261 P-glycoprotein (Pgp), a member of the ABC transporter fa

262 P-glycoprotein (Pgp), a member of the ATP-binding casset

263 of human cancers express multidrug-resistant P-glycoprotein (Pgp), which correlates with a poor progn

264 Both P-glycoprotein (Pgp)-dependent and non-Pgp-dependent mec

265 acyclines and other chemotherapeutics due to P-glycoprotein (pgp)-mediated export is a frequent probl

266 al cycle of the mouse ABC efflux transporter P-glycoprotein (Pgp; also known as ABCB1), which has a c

267 P-glycoprotein plays a key-protective role in buprenorph

268 The multispecific efflux transporter, P-glycoprotein, plays an important role in drug disposit

269 kinase (FAK), creating the occludin/ZO-1/FAK/P-glycoprotein regulatory complex.

270 s were studied using plethysmography and the P-glycoprotein role at the blood-brain barrier using in

271 PSC833-treated mice (p < .001), supporting a P-glycoprotein role in norbuprenorphine pharmacokinetics

272 nce predominantly involves overexpression of P-glycoprotein, so AZD2461 was developed as a poor subst

273 articipants had a baseline PET scan with the P-glycoprotein substrate (R)-[(11)C]verapamil.

274 ve, sodium channel blocker and a fluorescent p-glycoprotein substrate that was traceable.

275 d decreased by 50% brain accumulation of the P-glycoprotein substrate verapamil.

276 ed controls (n = 9) using PET with a labeled P-glycoprotein substrate, (11)C-verapamil, and (15)O-wat

277 tion of VEGF increased brain distribution of P-glycoprotein substrates morphine and verapamil, but no

278 increased brain uptake of three radiolabeled P-glycoprotein substrates, (3)H-verapamil (threefold inc

279 selected analogues into a homology model of P-glycoprotein suggest that benzophenones show an intera

280 interfere with the cellular defense protein P-glycoprotein, termed transporter interfering compounds

281 ications that markedly reduce recognition by P-glycoprotein, the key efflux transporter at the blood-

282 we have employed purified and reconstituted P-glycoprotein to study its interaction with ivacaftor a

283 SFN did not alter P-glycoprotein transport activity in brain and spinal co

284 C1P treatment induced P-glycoprotein transport activity in brain capillaries r

285 naling pathway that within minutes abolishes P-glycoprotein transport activity without altering trans

286 C1P induced P-glycoprotein transport activity without changing trans

287 g by sphingosine 1-phosphate decreases basal P-glycoprotein transport activity.

288 rough S1PR1 to rapidly and reversibly reduce P-glycoprotein transport activity.

289 a signaling cascade to dynamically regulate P-glycoprotein transport at the BBB and offers potential

290 The quiescent, nucleotide-free state in the P-glycoprotein transport cycle appears to bind ivacaftor

291 ed PCFT-nullizygous mice exhibited increased P-glycoprotein transport following VPA exposure.

292 c acid (VPA; 5 muM), significantly increased P-glycoprotein transport function in the wild-type anima

293 rather acts as a noncompetitive modulator of P-glycoprotein transport function.

294 However, VPA- or TCDD-induced P-glycoprotein transport was blocked in the PCFT-nullizy

295 f sterol and sphingolipid regulation of ABCB/P-glycoprotein transporters.

296 that is overexpressed in MDR cancer cells is P-glycoprotein, which actively effluxes drugs against a

297 The second ATPase is P-glycoprotein, which confers multidrug resistance, nota

298 The ABCB1 gene encodes P-glycoprotein, which limits brain concentrations of cer

299 ytochrome P450 3A, and the drug transporter, P-glycoprotein, which predisposes these agents to many d

300 oxin (TCDD), produced a similar induction of P-glycoprotein, which tightened the BBB, thereby increas